TABLE 1.
Baseline characteristics of COVID-19 patients.
| COVID-19 patients without cancer (N = 105), No. (%) | COVID-19 patients with cancer (N = 112), No. (%) | p value | |
|---|---|---|---|
| Age, median (IQR), year | 68.0 (57.0–73.5) | 65.0 (57.25–72.75) | 0.255 |
| Sex | |||
| Female | 51 (45.8) | 52 (46.4) | 0.752 |
| Male | 54 (54.2) | 60 (53.6) | |
| Comorbidities | |||
| Number of Comorbidities per patient >2 | 31 (29.5) | 27 (24.1) | 0.368 |
| Hypertension | 46 (43.8) | 33 (29.5) | 0.028 |
| Diabetes | 33 (31.4) | 20 (17.9) | 0.02 |
| Cardiovascular disease | 20 (19.0) | 10 (8.9) | 0.031 |
| Chronic lung disease | 5 (4.8) | 10 (8.9) | 0.227 |
| Chronic bronchitis | 1 (1.0) | 8 (7.1) | 0.036 |
| Hepatitis B | 3 (2.9) | 7 (6.3) | 0.386 |
| Common pulmonary infection | 3 (2.9) | 4 (3.6) | >0.99 |
| Anemia | 1 (1.0) | 5 (4.5) | 0.214 |
| Arrhythmia | 3 (2.9) | 4 (3.6) | >0.99 |
| Cerebrovascular disease | 6 (5.7) | 4 (3.6) | 0.668 |
| Pleural effusion | 0 (0) | 4 (3.6) | 0.122 |
| Hyperlipidemia | 6 (5.7) | 3 (2.7) | 0.32 |
| Chronic kidney disease | 5 (4.8) | 3 (2.7) | 0.488 |
| Severity of COVID-19 | |||
| Mild | 0 (0) | 0(0) | <0.001 |
| Moderate | 44 (41.9) | 14 (12.5) | |
| Severe | 45 (42.9) | 58 (51.8) | |
| Critical | 16 (15.2) | 40 (35.7) | |
| Clinical outcomes | |||
| Survival | 101 (96.2) | 94 (83.9) | 0.003 |
| Death | 4 (3.8) | 18 (16.1) | |
P Value indicate differences between COVID-19 patients without cancer and cancer patients with COVID-19; p < 0.05 was considered statistically significant.